Nov. 17, 2015
| By Mary Engel / Fred Hutch News Service
Media and online reactions to actor Charlie Sheen’s announcement Tuesday that he is HIV positive shows how far we have — and haven’t — come in the past three decades. Sheen is taking live-saving antiviral drugs. As long as he controls his virus with medication, he is likely to live a normal lifespan, Sheen's doctor said.
Science magazine selected HIV prevention trial for its top honor of 2011; study showed early antiretroviral therapy reduced heterosexual HIV transmission by 96 percent
Jan. 9, 2012
| By Colleen Steelquist and Dean Forbes
The Hutchinson Center's Statistical Center for HIV/AIDS Research & Prevention (SCHARP) played a key role in the HIV prevention study that Science magazine recently chose as its scientific breakthrough of the year for 2011.
Local collaborative research has far-reaching implications for autoimmunity, chronic infection control
July 25, 2011
A group of Seattle-based HIV/AIDS researchers, led by Seattle BioMed’s Dr. Helen Horton and including the Fred Hutchinson Cancer Research Center’s Drs. Julie McElrath and David Koelle of the Vaccine and Infectious Disease Division, detail one way long-term nonprogressors are able to control the disease in the July 17 online edition of Nature Medicine.
Supported by SCHARP’s data management, HIV Prevention Trials Network shows 96 percent reduction in HIV transmission to uninfected sexual partners
May 23, 2011
Men and women infected with HIV reduced the risk of transmitting the virus to their sexual partners by starting oral antiretroviral therapy, according to findings from a large multinational clinical study conducted by the HIV Prevention Trials Network, a global partnership dedicated to reducing the transmission of HIV through biomedical, behavioral, and structural interventions.
SCHARP data shows longer nevirapine treatment reduces infection by half for babies with HIV-infected mothers, 75 percent for infants of untreated moms
March 14, 2011
Giving breastfeeding infants of HIV-infected mothers a daily dose of the antiretroviral drug nevirapine for six months halved the risk of HIV transmission to the infants at age 6 months compared with giving infants the drug daily for six weeks, according to preliminary clinical trial data presented March 2 at the Retroviruses and Opportunistic Infections conference in Boston.